If preclinical findings were translated into clinic, they could shorten CAR-T generation lead time to one day.

The efficacy of IVIG in preventing GvHD has not been definitely demonstrated clinically. Using a xenogeneic model of GvHD in NOD/SCID/γc− (NSG) mice, we showed that weekly administration of ...

Using a multipronged strategy, Celyad is driving the development of next-generation chimeric antigen receptor-T cell-based therapies to treat cancer. Lead programs include both autologous and ...

The addition of post-transplant cyclophosphamide to sirolimus and cyclosporine reduced chronic GVHD. Efforts are needed to optimize cyclophosphamide dose to reduce toxicity. A novel regimen ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Itolizumab showed significant long-term benefits in acute GVHD, improving complete response duration and failure-free survival. Equillium, Inc. seeks Breakthrough Therapy designation and Accelerated ...

Home > Pressemitteilung: Chiara Bonini receives DKMS Mechtild ... DKMS recognizes outstanding research and supports young scientists in the field of stem cell transplantation and cell therapy for ...

Kadmon claimed approval for Rezurock (belumosudil) in July as a treatment for chronic graft versus host disease (GVHD) – a common and often fatal complication that can follow a bone marrow ...